Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.

Tau in the biological fluids (ECTAUSOME)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
CSF
Biomarker Measured
Tau
Use
Diagnostic
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Decipher the nature of Tau secreted in plasma and cerebrospinal fluids collected from healthy controls to AD patients, and to decipher if the presence of tau inside vesicles is influenced by the pathology.

Target Population/ Population Being Studied

People with asymptomatic cases with high risk to develop AD, isolated cognitive complaint, Prodromal AD, mild to moderate probable AD-type dementia, and healthy controls

Length of Current Trial
??
Number of Trial Participants

100

Estimated Trial Completion
December 2019
What is Required from Patients

blood draw, mild discomfort, in clinic visits OR noninvasive, at home kits that can take another form of bodily fluid (e.g., saliva)

What is Required from the Health System

phlebotomist (if the patient is using a blood sample), equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

University Hospital, Lille

“Ectosomes, New Biomarkers of Tau Pathology? (ECTAUSOME).” ClinicalTrials.gov. Accessed October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT03381482?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=2&rank=15